menu search

Roche's (rhhby) lunsumio application gets priority review

Roche's (RHHBY) BLA application seeking approval for the use of Lunsumio for relapsed or refractory fol...

July 6, 2022, 2:45 pm

Fate: possible speedy fda approval process with rmat designation

Meeting with FDA set for mid-2022 to discuss potential to begin pivotal trial using FT516 for patients with re...

June 3, 2022, 12:52 pm

Biomea fusion to present new preclinical data showing bmf-219's strong activity in relapsed/refractory chronic lymphocytic leukemia (cll) tumor models at asco 2022

REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to dis...

May 26, 2022, 6:30 pm

Fda places clinical hold on foghorn therapeutics' early-stage blood cancer trial

The FDA has instituted a clinical hold on Foghorn Therapeutics Inc's (NASDAQ: FHTX) Phase 1 dose-escalation study of FHD-286 in ...

May 20, 2022, 6:38 am

Springworks therapeutics: rating buy ahead of mid-year data releases

Data from Phase 3 trial for Nirogacestat in treating desmoid tumors and Phase 2 combination trial with anti-BCMA antibody Blenrep in ...

May 2, 2022, 5:42 pm

Lava therapeutics to present updated lava-051 clinical data at the 2022 american society of clinical oncology (asco) annual meeting

UTRECHT, The Netherlands and PHILADELPHIA, April 27, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focu...

April 27, 2022, 10:05 am

Gracell biotechnologies to present data at aacr annual meeting 2022 showcasing early first-in-human results for gc502 in r/r b-all

Allogeneic, off-the-shelf CAR-T therapy with CD19/CD7 dual-directed CAR shows promising early results in patients with r/r B-ALL PALO ALTO, Calif. and...

April 8, 2022, 4:00 pm

Bristol myers (bmy) gets ec nod for car t cell therapy breyanzi

The European Commission grants marketing authorization to Bristol Myers' (BMY) Breyanzi for treating certain forms of ...

April 6, 2022, 1:33 pm

Curis plummets to 52-week low after fda clinical hold on blood cancer trial

The FDA has placed a partial clinical hold on Curis Inc's (NASDAQ: CRIS) TakeAim Leukemia Phase 1/2a study in ...

April 4, 2022, 9:10 am

Why are tc biopharm shares trading higher today

The FDA has granted Orphan Drug designation to TC Biopharm Ltd's (NASDAQ: TCBP) lead product OmnImmune for use in Acute Myeloid Leukemia.  After ...

March 17, 2022, 11:51 am

Caribou biosciences to present preclinical data on cb-011, an immune-cloaked allogeneic anti-bcma car-t cell therapy, at the american association for cancer research (aacr) annual meeting

BERKELEY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharm...

March 8, 2022, 8:19 pm

Fda slams brakes on legend biotech's car-t therapy trial in lymphoma patients

The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901.  LB1901 is the company's investig...

February 15, 2022, 9:39 am

Fda slams brakes on legend biotech's car-t therapy trial in lymphoma patients

The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901.  LB1901 is the company's investig...

February 15, 2022, 9:39 am

Fda slams brakes on legend biotech's car-t therapy trial in lymphoma patients

The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901.  LB1901 is the company's investig...

February 15, 2022, 9:39 am

Moleculin biotech annamycin doublet therapy shows 68% overall survival in animal study

Moleculin Biotech Inc (NASDAQ: MBRX) has announced preliminary results supporting the successful conclusion of its second Phase 1 trial in Poland, ...

February 14, 2022, 2:10 pm

Moleculin biotech annamycin doublet therapy shows 68% overall survival in animal study

Moleculin Biotech Inc (NASDAQ: MBRX) has announced preliminary results supporting the successful conclusion of its second Phase 1 trial in Poland, ...

February 14, 2022, 2:10 pm

Moleculin biotech annamycin doublet therapy shows 68% overall survival in animal study

Moleculin Biotech Inc (NASDAQ: MBRX) has announced preliminary results supporting the successful conclusion of its second Phase 1 trial in Poland, ...

February 14, 2022, 2:10 pm

Fda lifts partial hold on kura oncology's early-stage leukemia trial

The FDA has lifted the partial clinical hold on Kura Oncology Inc (NASDAQ: KURA) KOMET-001 Phase 1b study of KO-539 in patients with ...

January 21, 2022, 5:49 am

Fda lifts partial hold on kura oncology's early-stage leukemia trial

The FDA has lifted the partial clinical hold on Kura Oncology Inc (NASDAQ: KURA) KOMET-001 Phase 1b study of KO-539 in patients with ...

January 21, 2022, 5:49 am

Fda lifts partial hold on kura oncology's early-stage leukemia trial

The FDA has lifted the partial clinical hold on Kura Oncology Inc (NASDAQ: KURA) KOMET-001 Phase 1b study of KO-539 in patients with ...

January 21, 2022, 5:49 am


Search within

Pages Search Results: